Eric Zhi
Impact in
-
- Multiple Myeloma Research and Treatments
-
- Peptidase Inhibition and Analysis
- CAR-T cell therapy research
- HER2/EGFR in Cancer Research
Papers in
- Oncology 9
- HER2/EGFR in Cancer Research 5
- PARP inhibition in cancer therapy 2
- Peptidase Inhibition and Analysis 2
- Cancer Treatment and Pharmacology 1
-
- Advanced Breast Cancer Therapies 7
- Co-authors
- Rita Nanda (4 shared papers)Sara A. Hurvitz (5 shared papers)Ashraf Badros (3 shared papers)Ira Gupta (3 shared papers)Sagar Lonial (3 shared papers)Suzanne Trudel (2 shared papers)Natalie S. Callander (2 shared papers)Hyo S. Han (5 shared papers)
- Journals
- ESMO Open (4 papers)Journal of Clinical Oncology (3 papers)Annals of Oncology (2 papers)Cancer Research (2 papers)Kidney International Reports (1 paper)
- Partner nations
- United StatesCanadaSwitzerland
In The Last Decade
Eric Zhi
12 papers receiving 86 citations
Peers
Comparison fields: 5 of 18
- Hematology 43
- Oncology 57
- Pulmonary and Respiratory Medicine 24
- Reproductive Medicine 6
- Molecular Biology 44
Countries citing papers authored by Eric Zhi
This map shows the geographic impact of Eric Zhi's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Eric Zhi with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Eric Zhi more than expected).
Fields of papers citing papers by Eric Zhi
This network shows the impact of papers produced by Eric Zhi. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Eric Zhi. The network helps show where Eric Zhi may publish in the future.
Co-authors
The 25 scholars most cited alongside Eric Zhi, linked wherever they have co-authored with each other. Click a name or a connecting line to browse the papers they share.
All Works
| # | Work | ||
|---|---|---|---|
| 1 | 2020 | 25 | |
| 2 | 2020 | 13 | |
| 3 | 2023 | 12 | |
| 4 | 2022 | 10 | |
| 5 | 2024 | 7 | |
| 6 | 2023 | 6 | |
| 7 | 2024 | 6 | |
| 8 | 2023 | 3 | |
| 9 | 2023 | 2 | |
| 10 | 2024 | 2 | |
| 11 | 2021 | 1 | |
| 12 | 2020 | 1 | |
| 13 | 2019 | 0 |
About Eric Zhi
Eric Zhi is a scholar working on Oncology, Pulmonary and Respiratory Medicine, Molecular Biology, Hematology and Organic Chemistry, having authored 13 papers that have together received 88 indexed citations. Recurring topics across this work include Advanced Breast Cancer Therapies (7 papers), Protein Degradation and Inhibitors (6 papers), HER2/EGFR in Cancer Research (5 papers), Multiple Myeloma Research and Treatments (3 papers), PARP inhibition in cancer therapy (2 papers), Peptidase Inhibition and Analysis (2 papers), Cancer Treatment and Pharmacology (1 paper) and Quinazolinone synthesis and applications (1 paper). The work is most often cited by research in Hematology (43 citations), Oncology (57 citations), Pulmonary and Respiratory Medicine (24 citations), Reproductive Medicine (6 citations) and Molecular Biology (44 citations). Eric Zhi has collaborated with scholars based in United States, Canada and Switzerland. Frequent co-authors include Rita Nanda, Sara A. Hurvitz, Ashraf Badros, Ira Gupta, Sagar Lonial, Suzanne Trudel, Natalie S. Callander, Hyo S. Han, Douglas W. Sborov and Attaya Suvannasankha. Their work appears in journals such as ESMO Open, Journal of Clinical Oncology, Annals of Oncology, Cancer Research and Kidney International Reports.
Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.